Prosecution Insights
Last updated: May 29, 2026
Application No. 18/560,771

PURIFICATION METHOD, SYSTEM AND DETECTION METHOD OF N-METHYLMORPHOLINE N-OXIDE, AND N-METHYLMORPHOLINE N-OXIDE OBTAINED THEREOF

Non-Final OA §101§102§112
Filed
Nov 14, 2023
Priority
May 18, 2021 — CN 202110521394.5 +1 more
Examiner
ROZOF, TIMOTHY R
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
B-FCTL Co., Ltd.
OA Round
1 (Non-Final)
73%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
97%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
693 granted / 955 resolved
+12.6% vs TC avg
Strong +24% interview lift
Without
With
+24.0%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 0m
Avg Prosecution
40 currently pending
Career history
989
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
23.9%
-16.1% vs TC avg
§102
28.4%
-11.6% vs TC avg
§112
21.4%
-18.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 955 resolved cases

Office Action

§101 §102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This is a response to Applicant’s communication filed on November 14, 2023. Application No. 18/560,771, is a 371 of PCT/CN2022/088743, filed April 24, 2022, and claims foreign priority to Chinese application No. CHINA 202110521394.5, filed May 18, 2021. In a preliminary amendment filed November 14, 2023, Applicant cancelled claims 11 and 16-20. Claims 1-10 and 12-15 are pending. Claim Rejections - 35 USC § 101 and/or 112(b) 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claim 10 is rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter, as well as rejected under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, regards as the invention. Claim 10 is drawn to an “application” of the N-methylmorpholine N-oxide (NMMO) in cellulose. The “application” of NMMO is equivalent to the “use” thereof. In this case, the “use” of NMMO does not fall within at least one of the four categories of patent eligible subject matter, and fails to recite steps under U.S.C. 101. In addition, claim 10 is also rejected under 35 U.S.C. 112(b) as being indefinite for reciting a use without any active, positive steps delimiting how this use is actually practiced. See MPEP 2173.05(q). Claim Rejections - 35 USC § 102(a)(1) The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-3, 9, and 12-15 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Scholten et al., U.S. Patent No. 4,748,241. Scholten discloses an industrial method of both purification and preparation of N-methylmorpholine N-oxide. See Scholten et al., ‘241 patent, Abstract; see also Id., Col. 1., ln. 50 – Col. 2, ln. 15, for commercial use and application. The method of Scholten reacts N-methylmorpholine in water with hydrogen peroxide at temperatures between 60-100 C, resulting 60% mass concentration of NMMO in the NMMO crude product. Id., Col. 2., lns. 16-43. Conclusion Claims 1-3, 9, 10, 12-15 are not allowed. Claims 4- 8 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to TIMOTHY R ROZOF whose telephone number is (571)270-5992. The examiner can normally be reached Monday - Friday, 9:00 a.m. -5:00 p.m.. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at (571) 272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TIMOTHY R ROZOF/ Primary Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

Nov 14, 2023
Application Filed
Apr 23, 2026
Non-Final Rejection mailed — §101, §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12636277
METHODS FOR TREATING DEVELOPMENTAL DYSPLASIS OF HIP
1y 0m to grant Granted May 26, 2026
Patent 12630532
Indole-substituted quinolines and their combination with Plk1 inhibitors for the treatment of cancer
2y 5m to grant Granted May 19, 2026
Patent 12622899
METHODS OF TREATING IDIOPATHIC PULMONARY FIBROSIS WITH DEUPIRFENIDONE
9m to grant Granted May 12, 2026
Patent 12616687
TREATMENT OF VIRAL INFECTION, DISEASE OR DISORDER USING A SELECTIVE S1R AGONIST
3y 6m to grant Granted May 05, 2026
Patent 12612365
COMPOUNDS AND METHODS FOR TREATING ALCOHOL DISORDER
4y 5m to grant Granted Apr 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
73%
Grant Probability
97%
With Interview (+24.0%)
2y 0m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 955 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month